Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Study ID
- NCT03609307
- Phase
- PHASE2/PHASE3
- Status
- Unknown
Conditions
- Age Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Combined Intravitreal bevacizumab and propranolol — DRUGthese patients receive two injections at each session Bavacizumab and propranolol
- Intravitreal bevacizumab — DRUGthese patients receive only Bevacizumab
Study Details
This study is designed to compare the effect of combined intravitreal Bevacizumab and Propranolol injection versus Bevacizumab monotherapy in patients with Age Related Macular Degeneration. Methods: In this study patients with Age Related Macular Degeneration who are naïve or had history of previous treatment are included. The eligible patients in randomized in two groups "Bevacizumab" and "Bavacizumab + propranolol" and in injected intravitreally for 3 times monthly. In "Bevacizumab+propranolol" group patients receive two injections at each session Bavacizumab and propranolol. In "Bevacizumab" group patients receive only Bevacizumab. The patients are followed for 6 months and central macular thickness and visual acuity is measured at baseline and monthly for 6 month. Baseline ancillary exams include Fluorescein Angiography and OCT-Angiography which is performed at the final exam as well. Patients needing any therapeutic intervention is addressed during the 6 month follow up period.
Key Dates
- First listed
- Aug 1, 2018
- Start date
- Sep 30, 2018
- Status verified
- Jul 2018
- Primary completion
- Oct 31, 2018
- Completion
- Feb 28, 2019
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: injection Combined Intravitreal bevacizumab and propranololpatients receive two injections at each session Bavacizumab
- Active Comparator: injection Intravitreal bevacizumabpatients receive only Bevacizumab
Primary Outcome Measure
Macular Thickness [ Time Frame: 1 month ]
Central Contacts
- Ramin Noorinia, MD009822591616
Related Studies
- Strategies for Improving Linkage-to-Care After Eye Disease ScreeningRecruiting · University of California, San Francisco · San Francisco, California
- Phase 1 Study of C.001 in Retinal DegenerationPHASE1 · Recruiting · Cellio Therapeutics Inc · Beverly Hills, California